The S&P 500 index has repeatedly scaled new all-time highs in recent months, a testament to robust corporate earnings and an enduring wave of optimism, largely fueled by advancements in Artificial Intelligence. This remarkable ascent, however, has ignited a fervent debate among financial analysts: are we witnessing a healthy
Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Bristol-Myers Squibb (BMY) is a top dividend stock with a 5.12% yield, strong profitability, and a solid financial health rating, making it a compelling choice for income investors.
Malcolm Ethridge from Capital Area Planning Group sees potential in ServiceNow, Inc. despite recent dip. Bristol-Myers and Live Nation also highlighted.
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts’ consensus estimates.
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to district court for further proceedings.
